Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Lexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases. Based in New York City, it focuses on treatments for heart health and other genetic diseases regardless of prevalence.
2 investors
Liberation Bioindustries provides a platform for rapid deployment of biomanufacturing capacity using precision fermentation for companies developing bio-based products.
2 investors
LifeDNA produces DNA-targeted supplements formulated based on genetic data to support specific health outcomes. The company offers personalized wellness products including sleep support and methylation support formulas for individual customers.
2 investors
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
2 investors
2 investors
Light Line Medical develops visible light technology for catheters that reduces infections and improves patient outcomes in minimally invasive medical procedures. The company serves healthcare providers and patients requiring catheter-based treatments across organ, vascular, and lymphatic systems.
2 investors
Lilac develops biological seed inoculants for legume crops, with PL11 designed to enhance nitrogen fixation and yield for yellow pea and lentil growers in the Northern Plains through engineered Rhizobium strains.
2 investors
Lime Therapeutics is a biotechnology company developing lipid-altering medicines for cancer, cardiometabolic diseases, lysosomal storage diseases, and neurodegenerative disorders. The company uses LipidSense, a proprietary ultrasensitive lipid detection platform, to discover and develop therapeutics targeting lipid dysfunction.
2 investors
Linear Diagnostics develops near-patient (point-of-care) diagnostic technology using EXPAR that delivers results in under 15 minutes, initially focused on detecting sexually transmitted infections and other infectious diseases. Its rapid testing is aimed at STI clinics to enable immediate treatment and reduce onward transmission.
2 investors
LinusBio develops precision medicine diagnostics based on exposome sequencing to identify biomarkers for complex conditions including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, and other diseases. The company serves physicians and patients seeking earlier detection and intervention for conditions that historically lacked molecular diagnostic endpoints.
2 investors
2 investors
Lir develops AI-driven viral vector engineering for gene therapy, using machine learning to optimize AAV (adeno-associated virus) vectors for improved dose efficiency, tissue targeting, and immune evasion.
2 investors
Living Models builds foundation models for biology, working at the intersection of AI and life sciences. Its team consists of PhDs and engineers with backgrounds from research and technology organizations.
2 investors
Lixa develops NeoX, an antimicrobial technology targeting antibiotic-resistant bacteria and biofilm fouling across pharmaceutical, industrial, food, and agricultural sectors. The company addresses antimicrobial resistance through a single mechanism that operates across multiple markets with multiple licensing pathways.
2 investors
Locksmith Bio applies physics-based AI models to characterise intrinsically disordered regions of proteins and identify potential binding sites within them. Its output is intended for biopharma research teams working on early-stage discovery programmes against targets that conventional approaches have not addressed.
2 investors
LogicBio is a biotechnology company focused on research and development of treatments for rare diseases, investigating new targets, modalities, and technologies for patients and their families worldwide.
2 investors
Longeveron is a clinical-stage biotechnology company developing allogeneic cellular therapies for life-threatening conditions affecting children and the elderly. Its investigational candidate is being evaluated for indications including Hypoplastic Left Heart Syndrome, Pediatric Dilated Cardiomyopathy, Alzheimer's Disease, and age-related frailty.
2 investors
Loop Genomics developed long-read sequencing technology that used synthetic long reads to enable full-length sequencing of DNA and RNA molecules on standard short-read sequencers. Acquired by Element Biosciences in 2021.
2 investors
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research. Founded in 2019 out of the Dementia Discovery Fund, it operates in the biotech and therapeutics sector.
2 investors
Building.life uses genetic engineering, genomic analysis, and AI to design novel organisms, beginning with engineering the world's first true unicorn through precision gene editing and embryonic development.
2 investors
2 investors
LSK Technologies builds a portable distributed testing platform for diagnosing infectious diseases in field and remote settings. The device, called PLUM, enables rapid and decentralized diagnostic testing for pathogens like Zika virus and SARS-CoV-2.
2 investors
EQT Life Sciences (formerly LSP) is one of Europe's largest life sciences investment firms that invests in innovative companies developing therapeutics, medical devices, diagnostics, and healthtech solutions. The firm targets companies with the potential to address unmet clinical needs and improve patient outcomes, with a 30-year track record and approximately 3.5 billion euros raised across multiple funds.
2 investors
Lubricin (PRG4) is a glycoprotein found naturally in the human body that lubricates and protects tissue surfaces from friction and wear. The company develops recombinant lubricin as a therapeutic agent to address inflammation-related conditions like dry eye and osteoarthritis.
2 investors